1. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study 
Wilbur H Chen, MD, Kathleen M Neuzil, MD, C Rebecca Boyce, RN, Marcela F Pasetti, PhD, Mardi K Reymann, BS, Lionel Martellet, MA, Nancy Hosken, PhD, F Marc LaForce, MD, Rajeev M Dhere, PhD, Sambhaji S Pisal, PhD, Amol Chaudhari, MD, Prasad S Kulkarni, MD, Ray Borrow, PhD, Helen Findlow, PhD, Valerie Brown, MS, Megan L McDonough, MPH, Len Dally, MSc, Mark R Alderson, PhD 
The Lancet Infectious Diseases 
Volume 18, Issue 10, Pages (October 2018)
DOI: /S (18)
Copyright © 2018 Elsevier Ltd Terms and Conditions

2. Figure
Trial profile
*Ten individuals were eligible at screening but were not enrolled for the following reasons: three could not commit the time; three were unable to be contacted; two screening window expired; one unsatisfied with study payment; and one self-report of influenza. †Aluminium-phosphate adjuvanted NmCV-5 vaccine. ‡One participant was unavailable for the day 8 clinic visit but was available for the follow-up visits on days 29 and 85.
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 Elsevier Ltd Terms and Conditions